New Opioid Overdose Treatment Approved in Vermont
In early August, the U.S. Food and Drug Administration (FDA) announced the approval of Zurnai, a groundbreaking sixth medication designed to reverse opioid overdoses. This automatic injection of nalmefene, produced by Purdue Pharma, represents a significant step in addressing the ongoing opioid crisis.
This development, while controversial due to the company’s past, is an important addition to the range of medications available to combat opioid overdoses. Nalmefene, which is more potent and has a longer duration of action than the commonly used naloxone, holds promise as a critical tool in emergency interventions.
